The Pharma Data

JANUARY 19, 2021

Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 It hopes to raise about $160 million in aggregate principal amount of 7.375% senior notes due 2025 and $270 million in aggregate principal amount of 7.250% senior notes due 2028. million shares of common stock at $14 per share, to raise $75.6

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. So it was that this sector was led by the Googles, Amazons, and Metas of the world, whose technological dominance allowed them to extend into pharmaceuticals. The next model of life had officially been released.

Engineering 144

Engineering Virus DNA Therapies 144

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52